

Is freeze dried plasma the solution to the plasma drought?

A retrieval / prehospital perspective

Aeromed 2025 Conference

Jon Newman | NSW Institute of Trauma and Injury Management



AGENCY FOR
**CLINICAL
INNOVATION**



Disclosures



Graphic content warning

Freeze-dried plasma administration in trauma

Review of literature and key findings

APRIL 2023



Contents

Executive summary	3	Safety profile	10	
Background	4	Adverse reactions	10	
	Who is this document for?	4	Infection risk	11
	What is plasma?	4	Efficacy	11
	Why an interest in plasma?	5	Where is FDP currently used?	12
	The challenges for NSW trauma	5	Availability	12
	Extended-life plasma explained	6	Product storage	12
	What is freeze-dried plasma?	6	ABO compatibility	13
	Why consider freeze-dried plasma?	6	Product administration and preparation time	14
Method	7	Cost to the health system	15	
	7	Summary of key findings – literature review	16	
	Question design	7	What are the potential implications for NSW?	17
	Document structure	7	Next steps	17
Search methodology	7	References	18	
Expert consensus	7		Appendix 1	22
Literature review	8	Glossary	23	
Mortality	8	Acknowledgements	26	
Intensive care unit and hospital length of stay	9			
Need for additional blood products	9			



Death from bleeding



Injury
Volume 48, Issue 1, January 2017, Pages 5-12

Trends in 1029 trauma deaths at a level 1 trauma center: Impact of a bleeding control bundle of care

Blessing T. Ovenivi, Erin E. Fox, Michelle Scerbo, Jeffrey S. Tomasek, Charles E. Wade, John B. Holcomb

Show more

Outline | Share | Cite

<https://doi.org/10.1016/j.injury.2016.10.037>

[Get rights and content](#)

Abstract

Background

Over the last decade the age of trauma patients and injury mortality has increased. At the same time, many centers have implemented multiple interventions focused on improved hemorrhage control, effectively resulting in a bleeding control bundle of care. The objective of our study was to analyze the temporal distribution of trauma-related deaths, the factors that characterize that distribution and how those factors have changed over time at our urban level 1 trauma center.

Methods


Records at an urban Level 1 trauma center were reviewed. Two time periods (2005–2006 and 2012–2013) were included in the analysis. Mortality rates were directly adjusted for age, gender and mechanism of injury. The Mann-Whitney and chi square tests were used to compare variables between periods, with significance set at 0.05.

Results

7080 patients (498 deaths) were examined in 2005–2006, while 8767 patients (531 deaths) were reviewed in 2012–2013. The median age increased 6 years, with a similar increase in those who died. In patients that died, no differences by gender, race or ethnicity were observed. Fall-related deaths are now the leading cause of death. Traumatic brain injury (TBI) and hemorrhage accounted

<https://www.sciencedirect.com/science/article/pii/S0020138316307148>

1/20



Death from bleeding



ELSEVIER

Critical Care Clinics
Volume 33, Issue 1, January 2017, Pages 15-36

Optimal Fluid Therapy for Traumatic Hemorrhagic Shock

Ronald Chang MD^a, John B. Holcomb MD^b

Show more

+ Add to Mendeley Share Cite






ORIGINAL ARTICLE



Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock


Authors: Jason L. Sperry, M.D., M.P.H., Francis X. Guyette, M.D., M.P.H., Joshua B. Brown, M.D., Mark H. Yazer, M.D., Darrell J. Triulzi, M.D., Barbara J. Early-Young, B.S.N., Peter W. Adams, B.S., [+18](#), for the PAMPer Study Group* [Author Info & Affiliations](#)

Are we providing everything the patient needs?



Distance / time

Resources Required (Blood products)



RTP

**BLEEDING PATIENT?
Handover Tool: C.L.O.T**

If advised EARLY, Massive Transfusion Protocol (MTP) can now be arranged for patients referred by medical control teams.

C L O T

C - CLINICAL REPORT
L - LABORATORY AND/OR SPECIALIST REPORT
O - OPERATIONAL STATUS
T - TRANSPORT PLAN

Massive Transfusion Packs should be considered for:

- All of hospital cases. Based from major trauma centres
- Emergency patients
- For reference on each flow case
- Patients bleeding to major trauma hospitals



Call the State Retrieval Consultant AS SOON AS POSSIBLE
9553 2222

NSW Ambulance excellence in care

ITRACC 2.2
Information system for Trauma, Retrieval and Critical Care

Filter | Reset | Settings | Info

LOCATION
 Post address or landmark:
 (35.542857° S, 151.382333° E)
 GMS | OSM | OSM

Show blood count



TOTAL BLOOD PRODUCTS

RBC	FFP	Platelets	Crye
58	50	2	30

▼ **BLOOD PRODUCTS: HAS BLOOD PRODUCTS**

Tamworth Rural Referral Hospital
 Blood Bank (02 9367 7816)
 (0 km from location, 50 km away)

RBC	FFP	Platelets	Crye
42	50	2	30

Retrieval Services - ELP



Plasma Drought?






Freeze Dried Plasma

Why Freeze-Dried Plasma?

It's Plasma!!

Logistic advantage over FFP



Is FDP a reasonable alternative to FFP?

EVIDENCE SERIES

Freeze-dried plasma administration in trauma

Review of literature and key findings

APRIL 2023


Contents

Executive summary	3	Safety profile	10
Background	4	Adverse reactions	10
Why is this document for?	4	Infection risk	10
What is planned?	4	Efficacy	10
Why an interest in plasma?	4	Where is FDP currently used?	10
The challenges for FFP income	5	Availability	10
Shouldn't the plasma be frozen?	5	Product storage	10
What is freeze disruption?	5	ABO compatibility	10
Why consider freeze dried plasma?	5	Product administration and preservation time	14
		Cost to the health system	15
Method	7	Summary of key findings - literature review	16
Question design	7	What are the potential implications for FFP?	17
Document structure	7	Next steps	17
Search methodology	7	References	18
Expert consensus	7	Appendix 1	20
Literature review	8	Glossary	23
Morality	8	Acknowledgements	26
Intensive care unit and hospital length of stay	8		
Need for additional blood products	8		

The NSW Institute of Trauma and Injury Management
Trauma Innovation Committee



Mortality
Additional blood products
Safety
Efficacy
ICU / hosp LOS



VS



Mortality

Table 2: Studies comparing FDP to FFP on mortality

Author group	Mortality control (FFP)	Mortality intervention (FDP)	p-value
Nguyen et al.³⁹	N = 29	N = 43	
24 hour	9 (31%)	9 (21%)	0.591
Haemorrhage-related	5 (17%)	3 (7%)	0.293
28 day	10 (34%)	11 (26%)	0.703
Garrigue et al.³⁴	N = 24	N = 23	
All cause in-hospital within 30 days	7 (29%)	5 (22%)	0.56


Need for additional blood products

French lyophilized plasma versus fresh frozen plasma for the initial management of trauma-induced coagulopathy: a randomized open-label trial

D Garrigue ^{1 2}, A Godier ^{3 4}, A Glacet ^{1 2}, J Labreuche ⁵, E Kipnis ^{1 6}, C Paris ⁷, A Duhamel ⁵, E Resch ⁸, A Bauters ⁷, F Machuron ⁵, P Renom ⁷, P Goldstein ^{1 2}, B Tavernier ¹, A Sailliol ⁹, S Susen ^{7 10}

Affiliations + expand

PMID: 29274254 DOI: [10.1111/jth.13929](https://doi.org/10.1111/jth.13929)



~~FDP required less Fibrinogen (median 2gms vs 3gm)~~
RCC & Crystalloids demands were equal.

Use of French lyophilized plasma transfusion in severe trauma patients is associated with an early plasma transfusion and early transfusion ratio improvement.

Nguyen C ¹, Bordes J, Cungi PJ, Esnault P, Cardinale M, Mathais Q, Cotte J, Beaume S, Sailliol A, Prunet B, Meaudre E

Author information ▶

The Journal of Trauma and Acute Care Surgery. 01 May 2018, 84(5):780-785
<https://doi.org/10.1097/ta.0000000000001801> PMID: 29334571



Significantly fewer cases of massive transfusion in the FLYP group – 7% vs 45% P < 0.0001

Safety profile

Reported adverse reactions 2007-2011 in Germany*

Adverse reactions	LyoPlas (n=237,850 units)	FFP (n= 343,821 units)
Urticaria	54	63
Fever	24	14
Severe hypotonia including anaphylactic shock	3	5
Bronchospasm	1	3
Transfusion-related acute lung injury (TRALI)	None reported*	None reported*

*Safety procedures using plasma only from male donors and female donors without children or female donors with children having additional antibodies screening have been in place from 2006. This likely accounts for the absence of TRALI cases in both groups.



Efficacy

1. Freeze-dried plasma for major trauma – Systematic review and meta-analysis

Garrick Mok ¹, Richard Hoang, Montaha Wajid Khan, Dylan Pannell, Henry Peng, Homer Tien, Avery Nathens, Jeannie Callum, Keyvan Karkouti, Andrew Beckett, Luis Teodoro da Luz

Affiliations + expand

PMID: 33507025 PMCID: PMC7899224 DOI: 10.1097/TA.00000000000003012



Effects on coagulation parameters
INR, Prothrombin time, TEG
No difference.

2. French lyophilized plasma versus fresh frozen plasma for the initial management of trauma-induced coagulopathy: a randomized open-label trial

D Garrigue ^{1 2}, A Godier ^{3 4}, A Glacet ^{1 2}, J Labreuche ⁵, E Kipnis ^{1 6}, C Paris ⁷, A Duhamel ⁵, E Resch ⁸, A Bauters ⁷, F Machuron ⁵, P Renom ⁷, P Goldstein ^{1 2}, B Tavernier ¹, A Sailliol ⁹, S Susen ^{7 10}

Affiliations + expand

PMID: 29274254 DOI: 10.1111/jth.13929



n=48
FLyP more rapid & longer lasting effect
on fibrinogen levels.

3. Use of French lyophilized plasma transfusion in severe trauma patients is associated with an early plasma transfusion and early transfusion ratio improvement.

Nguyen C ¹, Bordes J., Cungi P.J., Esnault P., Cardinale M., Mathias Q., Cotte J., Beaume S., Sailliol A., Prunet B., Meaudre E

Author information ▶

The Journal of Trauma and Acute Care Surgery, 01 May 2018, 84(5):780-785
<https://doi.org/10.1097/ta.00000000000001801> PMID: 29334571




n=43
No difference in Fibrinogen levels

Is FDP a reasonable
alternative to FFP?

Yes, it is!

SO WHAT?



Next
steps

Freeze-dried plasma administration in trauma

Review of literature and key findings

APRIL 2023

Contents

Executive summary	3	Safety profile	10
Background	4	Adverse reactions	10
Who is this document for?	4	Infection risk	11
What is plasma?	4	Efficacy	11
Why an interest in plasma?	5	Where is FDP currently used?	12
The challenges for NSW trauma	5	Availability	12
Extended-life plasma explained	6	Product storage	12
What is freeze-dried plasma?	6	ABO compatibility	13
Why consider freeze-dried plasma?	6	Product administration and preparation time	14
		Cost to the health system	15
Method	7	Summary of key findings – literature review	16
Question design	7	What are the potential implications for NSW?	17
Document structure	7	Next steps	17
Search methodology	7	References	18
Expert consensus	7	Appendix 1	22
Literature review	8	Glossary	23
Mortality	8	Acknowledgements	26
Intensive care unit and hospital length of stay	9		
Need for additional blood products	9		

Pre-hospital freeze-dried plasma for critical bleeding after trauma: A pilot randomized controlled trial

Biswadev Mitra^{1 2}, Ben Meadley^{3 4}, Stephen Bernard^{2 4 5}, Marc Maegele^{6 7}, Russell L Gruen⁸, Olivia Bradley⁴, Erica M Wood^{2 9}, Zoe K McQuilten^{2 9}, Mark Fitzgerald^{10 11 12}, Toby St Clair^{3 4}, Andrew Webb¹³, David Anderson^{3 4 5}, Michael C Reade^{2 14 15 16}

Affiliations + expand

PMID: 37103482 PMID: PMC10946458 DOI: 10.1111/acem.14745

Abstract

Objectives: Transfusion of a high ratio of plasma to packed red blood cells (PRBCs), to treat or prevent acute traumatic coagulopathy, has been associated with survival after major trauma. However, the effect of prehospital plasma on patient outcomes has been inconsistent. The aim of this pilot trial was to assess the feasibility of transfusing freeze-dried plasma with red blood cells (RBCs) using a randomized controlled design in an Australian aeromedical prehospital setting.

Methods: Patients attended by helicopter emergency medical service (HEMS) paramedics with suspected critical bleeding after trauma managed with prehospital RBCs were randomized to receive 2 units of freeze-dried plasma (Lyoplas N-w) or standard care (no plasma). The primary outcome was the proportion of eligible patients enrolled and provided the intervention. Secondary outcomes included preliminary data on effectiveness, including mortality censored at 24 h and at hospital discharge, and adverse events.

Results: During the study period of June 1 to October 31, 2022, there were 25 eligible patients, of whom 20 (80%) were enrolled in the trial and 19 (76%) received the allocated intervention. Median time from randomization to hospital arrival was 92.5 min (IQR 68–101.5 min). Mortality may have been lower in the freeze-dried plasma group at 24 h (RR 0.24, 95% CI 0.03–1.73) and at hospital discharge (RR 0.73, 95% CI 0.24–2.27). No serious adverse events related to the trial interventions were reported.

Conclusions: This first reported experience of freeze-dried plasma use in Australia suggests prehospital administration is feasible. Given longer prehospital times typically associated with HEMS attendance, there is potential clinical benefit from this intervention and rationale for a definitive trial.

The logo for CSL, consisting of the letters 'CSL' in a large, bold, red, sans-serif font.

Conclusion on Freeze Dried Plasma



Evidence driven not barriers



FDP comparable to FFP logistic advantage




FDP..... Greatest benefit = Rural prehosp & retrieval



We all have a part to play!



FDP can be a solution to the plasma drought



Thank you



AGENCY FOR
**CLINICAL
INNOVATION**

1 Reserve Rd
St Leonards NSW 2065

T + 61 2 9464 4666

F + 61 2 9464 4728

aci-info@health.nsw.gov.au

www.aci.health.nsw.gov.au